Elite Journal of Health Sciences. Volume 2 issue 6(2024), Pp. 28-39
https://epjournals.com/journals/EJHS

Free Radical-Induced Hemoglobin Modifications in Sickle Cell Disease

Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda

emmanuelobeagu@yahoo.com

Abstract

Sickle Cell Disease (SCD) is characterized by the presence of abnormal hemoglobin S (HbS), which leads to the formation of sickle-shaped red blood cells. This genetic disorder is associated with increased oxidative stress and the production of reactive oxygen species (ROS), which induce significant hemoglobin modifications. Free radical-induced hemoglobin modifications, such as oxidation, hemichrome formation, and covalent cross-linking, contribute to the pathophysiology of SCD by impairing red blood cell function and stability. These oxidative modifications destabilize the red blood cell membrane, leading to hemolysis, reduced deformability, and increased cell adhesion, which exacerbates vaso-occlusive crises. The release of free heme from hemolyzed cells promotes inflammation and vascular damage, further complicating the clinical presentation of SCD. Therapeutic approaches, including antioxidant therapy, HbS polymerization inhibitors, and heme scavengers, aim to mitigate the oxidative damage and improve patient outcomes. Future research focusing on novel antioxidants, gene therapy, and advanced therapeutic strategies holds promise for reducing the oxidative burden and enhancing the quality of life for individuals with SCD.

Keywords: *Sickle Cell Disease**,** Hemoglobin Modifications**,** Oxidative Stress**,** Free Radicals**,** Antioxidant Therapy*

Introduction

Sickle Cell Disease (SCD) is a hereditary blood disorder caused by a mutation in the β-globin gene, leading to the production of an abnormal form of hemoglobin known as hemoglobin S (HbS). Under low oxygen conditions, HbS polymerizes, causing red blood cells (RBCs) to adopt a characteristic sickle shape. This morphological change in RBCs results in various clinical complications, including chronic hemolytic anemia, vaso-occlusive crises (VOCs), and organ damage. The pathophysiology of SCD is complex and multifaceted, involving numerous cellular and molecular mechanisms. Among these, oxidative stress and the production of reactive oxygen species (ROS) play a central role. The chronic hemolysis and recurrent ischemia-reperfusion injury associated with SCD result in elevated ROS levels, contributing significantly to the disease's progression and severity. These ROS are highly reactive molecules capable of damaging cellular components, including lipids, proteins, and nucleic acids. Hemoglobin, the oxygen-carrying protein in RBCs, is particularly susceptible to oxidative damage. The presence of HbS exacerbates

this vulnerability, as it is more prone to oxidation than the normal hemoglobin A (HbA). Free radicals, such as superoxide anions, hydrogen peroxide, and hydroxyl radicals, interact with hemoglobin, leading to various modifications that impair its function and stability. These oxidative modifications are crucial in the pathogenesis of SCD and significantly impact RBC physiology and lifespan.[1-10]

One major consequence of oxidative stress in SCD is the formation of methemoglobin (metHb), where the iron in the heme group is oxidized from the ferrous (Fe2+) to the ferric (Fe3+) state. Methemoglobin cannot bind oxygen effectively, reducing the oxygen-carrying capacity of RBCs. Additionally, oxidative stress promotes the formation of hemichromes, which are denatured hemoglobin derivatives. Hemichromes further destabilize the RBC membrane, making cells more susceptible to hemolysis and reducing their deformability. Oxidative stress also leads to the covalent cross-linking of hemoglobin molecules, resulting in the formation of large aggregates. These aggregates can precipitate within RBCs, forming Heinz bodies, which are indicative of oxidative damage. Heinz bodies contribute to the structural instability of RBCs and their premature destruction in the spleen, exacerbating the chronic hemolytic anemia seen in SCD patients. The structural and functional impairments caused by oxidative modifications of hemoglobin have profound implications for RBCs in SCD. Membrane instability and decreased deformability lead to the destruction of RBCs and a shortened lifespan. Additionally, oxidative damage enhances the adhesive properties of RBCs to the endothelium, promoting vaso-occlusion—a hallmark of SCD that leads to painful VOCs and contributes to tissue ischemia and organ damage.[11-15]

Inflammation and vascular damage are further exacerbated by the release of free heme from lysed RBCs. Free heme is highly pro-inflammatory and can induce endothelial injury, thereby perpetuating the cycle of vaso-occlusion and inflammation. This chronic inflammatory state contributes to the long-term complications of SCD, including stroke, acute chest syndrome, and renal dysfunction. Given the significant role of oxidative stress and free radical-induced hemoglobin modifications in SCD, therapeutic interventions targeting these pathways are of great interest. Antioxidant therapy, including agents like N-acetylcysteine (NAC) and vitamin E, aims to reduce oxidative stress by scavenging free radicals. Additionally, therapies that increase the production of fetal hemoglobin (HbF), such as hydroxyurea, have shown efficacy in reducing oxidative damage by inhibiting HbS polymerization. The use of heme scavengers, such as haptoglobin and hemopexin, also holds promise in mitigating the oxidative and pro-inflammatory effects of free heme. These therapies can help manage the oxidative burden in SCD and improve patient outcomes.[16-20]

Oxidative Stress in Sickle Cell Disease

Oxidative stress is a prominent and detrimental feature in the pathophysiology of Sickle Cell Disease (SCD). It arises from an imbalance between the production of reactive oxygen species (ROS) and the body's ability to detoxify these reactive intermediates or repair the resulting damage. In SCD, the continuous and recurrent processes of hemolysis and vaso-occlusion significantly contribute to heightened oxidative stress, exacerbating the disease's clinical manifestations and complications. The generation of ROS in SCD occurs through several mechanisms. Hemolysis, a

hallmark of SCD, leads to the release of free hemoglobin into the plasma, where it can undergo auto-oxidation. This process generates superoxide anions, which are rapidly converted into hydrogen peroxide by superoxide dismutase. Furthermore, the ischemia-reperfusion injury that accompanies vaso-occlusive crises results in an influx of oxygen to previously deprived tissues, leading to the rapid generation of ROS. Additionally, inflammatory cells such as neutrophils and macrophages, which are activated during inflammatory responses, produce large amounts of ROS as part of their antimicrobial activities. The ROS generated in SCD have several deleterious effects on red blood cells (RBCs) and other cellular components. One of the primary targets of ROS is hemoglobin, particularly the abnormal hemoglobin S (HbS). Oxidative modifications of HbS include the formation of methemoglobin (metHb), where the iron in the heme group is oxidized to the ferric state, impairing its oxygen-carrying capacity. MetHb can further propagate oxidative damage by catalyzing the formation of additional ROS through the Fenton reaction, wherein hydrogen peroxide is converted to highly reactive hydroxyl radicals.[21-30]

Another significant consequence of oxidative stress in SCD is the formation of hemichromes, which are denatured hemoglobin derivatives. These hemichromes can bind to the RBC membrane, causing structural destabilization and increasing the cells' susceptibility to hemolysis. The oxidative modification of membrane proteins and lipids further contributes to RBC rigidity and deformability, promoting their premature destruction in the spleen and worsening hemolytic anemia. Oxidative stress also impacts the adhesion properties of RBCs. Modified hemoglobin and damaged membranes can expose phosphatidylserine and other adhesion molecules on the RBC surface, enhancing their interaction with the endothelium and other blood cells. This increased adhesion is a critical factor in the pathogenesis of vaso-occlusive crises, as it facilitates the occlusion of small blood vessels, leading to tissue ischemia, pain, and organ damage. The effects of oxidative stress extend beyond RBCs to other cellular and vascular components. Endothelial cells, which line the blood vessels, are particularly vulnerable to oxidative damage. ROS can induce endothelial dysfunction by promoting the expression of adhesion molecules, cytokines, and other pro-inflammatory mediators. This not only exacerbates vaso-occlusion but also contributes to chronic inflammation, a characteristic feature of SCD.[31-35]

Inflammation and oxidative stress form a vicious cycle in SCD. The inflammatory response to hemolysis and tissue ischemia leads to the recruitment and activation of leukocytes, which in turn produce more ROS. This perpetuates oxidative damage, further aggravating the disease's complications. The chronic inflammatory state in SCD is associated with various long-term complications, including organ damage, stroke, and pulmonary hypertension. Given the central role of oxidative stress in SCD, therapeutic strategies aimed at reducing oxidative damage are of significant interest. Antioxidants such as N-acetylcysteine (NAC) and vitamin E have been investigated for their potential to scavenge free radicals and reduce oxidative stress. Clinical studies have shown that these antioxidants can improve RBC survival and reduce hemolysis in SCD patients. Moreover, therapies that increase the production of fetal hemoglobin (HbF), such as hydroxyurea, can reduce the polymerization of HbS and the subsequent oxidative stress.[36-38]

Free Radical-Induced Hemoglobin Modifications

In Sickle Cell Disease (SCD), the abnormal hemoglobin S (HbS) is highly susceptible to oxidative stress, resulting in various free radical-induced modifications. These modifications impair hemoglobin function and red blood cell (RBC) integrity, contributing to the disease's pathophysiology. One of the primary oxidative modifications in SCD is the oxidation of hemoglobin to form methemoglobin (metHb). In metHb, the iron in the heme group is oxidized from the ferrous (Fe2+) to the ferric (Fe3+) state, rendering it incapable of binding and transporting oxygen. This process not only reduces the oxygen-carrying capacity of RBCs but also contributes to oxidative stress. MetHb can further catalyze the formation of reactive oxygen species (ROS) through the Fenton reaction, where hydrogen peroxide is converted into highly reactive hydroxyl radicals. The accumulation of metHb and ROS exacerbates oxidative damage within RBCs. Hemichromes are another significant oxidative modification observed in SCD. Hemichromes are denatured hemoglobin derivatives formed when hemoglobin undergoes oxidative damage. These denatured forms of hemoglobin have a high affinity for binding to the RBC membrane, where they precipitate and cause membrane instability. Hemichromes can also bind to band 3 proteins on the RBC membrane, promoting the formation of membrane clusters and leading to the exposure of phosphatidylserine on the cell surface. This exposure signals macrophages to clear these damaged cells from the circulation, contributing to the chronic hemolysis observed in SCD.[39-47]

Oxidative stress can induce covalent cross-linking of hemoglobin molecules, leading to the formation of large aggregates. These aggregates can precipitate within RBCs to form Heinz bodies, which are inclusions composed of denatured hemoglobin. Heinz bodies are indicative of severe oxidative damage and contribute to the structural instability and rigidity of RBCs. The presence of Heinz bodies makes RBCs more prone to splenic sequestration and destruction, further exacerbating hemolytic anemia in SCD patients. The oxidative modifications of hemoglobin have profound effects on the RBC membrane. Oxidative damage to membrane proteins and lipids compromises the structural integrity and deformability of RBCs. The resulting membrane instability leads to increased RBC rigidity, making them less able to navigate the microvasculature and more likely to become trapped in the spleen or adhere to the endothelium. This increased adhesion is a critical factor in vaso-occlusive crises (VOCs), as it promotes the occlusion of small blood vessels and contributes to tissue ischemia and pain. The free heme released from hemolyzed RBCs is highly pro-inflammatory and can induce significant vascular damage. Free heme promotes the activation of endothelial cells, leading to the expression of adhesion molecules and the recruitment of inflammatory cells. This vascular inflammation exacerbates the vaso-occlusive process and contributes to the chronic inflammatory state observed in SCD. Additionally, free heme can catalyze the formation of ROS, further perpetuating oxidative damage and inflammation. Addressing free radical-induced hemoglobin modifications in SCD requires targeted therapeutic approaches. Antioxidant therapy aims to reduce oxidative stress by scavenging free radicals and protecting hemoglobin from oxidative damage. Agents such as N-acetylcysteine (NAC) and vitamin E have shown potential in reducing oxidative damage and improving RBC survival. Additionally, therapies that increase the production of fetal hemoglobin (HbF), such as hydroxyurea, can reduce HbS polymerization and subsequent oxidative stress. Emerging therapies focus on neutralizing the effects of free heme and hemoglobin. Heme scavengers, such as haptoglobin and hemopexin, bind free hemoglobin and heme, reducing their pro-oxidant and pro-

inflammatory effects. These therapies can help manage the oxidative burden in SCD and mitigate the complications associated with free radical-induced hemoglobin modifications.[48-57]

Impact on Red Blood Cells

In Sickle Cell Disease (SCD), the oxidative modifications of hemoglobin have profound and far-reaching effects on the physiology and function of red blood cells (RBCs). These changes compromise RBC integrity, leading to a cascade of detrimental effects that exacerbate the clinical complications associated with SCD. One of the primary impacts of oxidative stress on RBCs is the destabilization of the cell membrane. The oxidative modification of hemoglobin leads to the formation of hemichromes, which bind to the RBC membrane and promote the aggregation of membrane proteins. This aggregation disrupts the normal architecture of the membrane, making it more susceptible to fragmentation and hemolysis. The release of hemoglobin into the bloodstream from lysed RBCs contributes to the overall oxidative burden and perpetuates a cycle of damage and destruction. The compromised membrane integrity also results in the exposure of phosphatidylserine on the outer leaflet of the cell membrane. This exposure serves as an "eat-me" signal for macrophages, leading to the premature clearance of RBCs from the circulation. The chronic hemolysis observed in SCD patients contributes to the persistent anemia and necessitates frequent blood transfusions. Normal RBCs are highly deformable, allowing them to navigate through the narrow and tortuous microvasculature efficiently. However, in SCD, oxidative damage to the cytoskeletal proteins and lipids in the RBC membrane reduces the cells' deformability. This rigidity is further compounded by the presence of hemoglobin aggregates and Heinz bodies, which physically obstruct the flexibility of the cells. As a result, sickle cells are less able to deform and are more likely to become trapped in the microvasculature, leading to vaso-occlusion and subsequent ischemic damage to tissues and organs.[58-63]

Oxidative stress enhances the adhesive properties of RBCs, significantly contributing to the pathogenesis of vaso-occlusive crises (VOCs). Oxidatively modified hemoglobin and damaged membrane proteins upregulate the expression of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) on the RBC surface. These adhesion molecules facilitate the binding of sickle cells to the endothelial cells lining the blood vessels, promoting vaso-occlusion. The increased adhesion of RBCs to the endothelium not only obstructs blood flow but also triggers an inflammatory response, further exacerbating vascular damage and promoting a cycle of occlusion, inflammation, and pain. This mechanism is central to the acute and chronic complications of SCD, including pain crises, acute chest syndrome, and organ damage. The hemolysis of oxidatively damaged RBCs releases free heme into the circulation. Free heme is highly pro-inflammatory and can induce significant endothelial damage. It activates endothelial cells, leading to the expression of additional adhesion molecules and the recruitment of leukocytes. This inflammatory response contributes to the chronic vascular inflammation observed in SCD, which is a key factor in the development of complications such as stroke, pulmonary hypertension, and chronic kidney disease.[64-69]

The oxidative modifications of hemoglobin and the resultant membrane damage significantly shorten the lifespan of RBCs in SCD. Normal RBCs have a lifespan of approximately 120 days,

but sickle cells often survive for only 10-20 days. This drastically reduced lifespan contributes to the persistent anemia and the need for increased erythropoiesis, which can strain the bone marrow and lead to complications such as bone pain and skeletal abnormalities. Addressing the impact of oxidative stress on RBCs in SCD requires targeted therapeutic interventions. Antioxidant therapy, including agents like N-acetylcysteine (NAC) and vitamin E, aims to reduce oxidative damage by scavenging free radicals. These therapies can help stabilize the RBC membrane, reduce hemolysis, and improve RBC deformability. Additionally, increasing the production of fetal hemoglobin (HbF) through agents such as hydroxyurea can inhibit HbS polymerization, reducing oxidative stress and its associated effects on RBCs.[70]

Therapeutic Interventions

Addressing the oxidative stress and free radical-induced hemoglobin modifications in Sickle Cell Disease (SCD) requires a multifaceted approach. Various therapeutic strategies aim to reduce oxidative damage, improve red blood cell (RBC) stability, and alleviate the clinical complications associated with SCD. These interventions include antioxidant therapy, HbS polymerization inhibitors, heme scavengers, and emerging gene therapies.

Antioxidant Therapy

Antioxidants are compounds that can neutralize reactive oxygen species (ROS) and reduce oxidative stress. In SCD, antioxidant therapy aims to protect RBCs from oxidative damage and improve their survival. N-Acetylcysteine (NAC) is a precursor to glutathione, a major intracellular antioxidant. By replenishing glutathione levels, NAC helps scavenge ROS and reduce oxidative stress. Clinical studies have shown that NAC can decrease markers of oxidative damage, reduce hemolysis, and improve RBC survival in SCD patients. Vitamin E is a lipid-soluble antioxidant that protects cell membranes from oxidative damage. It has been shown to reduce the formation of oxidized hemoglobin and improve RBC deformability. Supplementation with vitamin E has demonstrated potential benefits in reducing oxidative stress and improving hematological parameters in SCD patients. Various other antioxidants, including ascorbic acid (vitamin C), selenium, and polyphenols, are being explored for their potential benefits in SCD. These antioxidants can work synergistically to mitigate oxidative damage and improve overall RBC health.[71]

HbS Polymerization Inhibitors

The polymerization of hemoglobin S (HbS) under low oxygen conditions is a critical factor in the pathophysiology of SCD. Inhibiting HbS polymerization can reduce sickling, oxidative stress, and subsequent hemolysis. Hydroxyurea is an established treatment for SCD that increases the production of fetal hemoglobin (HbF). HbF interferes with HbS polymerization, reducing the formation of sickled cells. Hydroxyurea has been shown to decrease the frequency of vaso-occlusive crises (VOCs), reduce hemolysis, and improve overall survival in SCD patients. Additionally, it has antioxidant properties that further mitigate oxidative stress.[72]

Heme Scavengers

Free heme released from lysed RBCs is highly pro-inflammatory and contributes to oxidative stress. Heme scavengers bind free hemoglobin and heme, neutralizing their harmful effects. Haptoglobin binds free hemoglobin released during hemolysis, forming a complex that is rapidly cleared by the liver. This reduces the availability of free hemoglobin to catalyze the formation of ROS, thereby mitigating oxidative stress and inflammation. Hemopexin binds free heme with high affinity, preventing its pro-oxidant and pro-inflammatory effects. The heme-hemopexin complex is also cleared by the liver, reducing the oxidative burden in SCD patients. Supplementation with hemopexin has shown potential in reducing heme-induced vascular damage and inflammation.[73]

Emerging Therapies

Research is ongoing to develop novel therapies that target the root causes of SCD and provide more effective management of the disease. Gene therapy aims to correct the genetic defect responsible for SCD. Techniques such as CRISPR/Cas9-mediated gene editing can potentially repair or replace the mutated β-globin gene, restoring normal hemoglobin production. Early clinical trials have shown promising results, with some patients achieving sustained increases in HbF levels and reduced disease severity. Hematopoietic stem cell transplantation (HSCT) is a curative treatment for SCD. Transplanting healthy stem cells from a compatible donor can replace the patient's defective blood cells with normal ones. Advances in HSCT techniques, including reduced-intensity conditioning and the use of haploidentical donors, are expanding the availability of this treatment to more patients. New small molecule drugs are being developed to inhibit HbS polymerization, reduce oxidative stress, and improve RBC survival. For example, voxelotor, a hemoglobin oxygen-affinity modulator, stabilizes HbS in its oxygenated state, reducing sickling and hemolysis. Other small molecules targeting various pathways involved in SCD pathogenesis are also under investigation.[72-73]

Conclusion

The management of Sickle Cell Disease (SCD) necessitates a comprehensive understanding of the disease's underlying mechanisms, particularly the role of oxidative stress and free radical-induced hemoglobin modifications. These processes are central to the pathophysiology of SCD, contributing to hemolysis, reduced red blood cell (RBC) deformability, increased adhesion, and chronic inflammation. These factors collectively lead to the frequent and severe clinical complications associated with the disease, such as vaso-occlusive crises (VOCs), chronic anemia, and organ damage. Therapeutic strategies targeting oxidative stress and its effects on hemoglobin and RBCs offer significant promise in improving patient outcomes. Antioxidant therapies, such as N-acetylcysteine (NAC) and vitamin E, aim to mitigate oxidative damage by scavenging reactive oxygen species (ROS), thereby protecting RBCs from premature destruction. HbS polymerization inhibitors like hydroxyurea reduce the formation of sickled cells and subsequent oxidative stress, demonstrating considerable efficacy in clinical practice.

Furthermore, the use of heme scavengers, such as haptoglobin and hemopexin, addresses the harmful effects of free heme released during hemolysis, reducing vascular inflammation and oxidative burden. These interventions, along with emerging treatments like gene therapy and novel small molecules, represent a promising frontier in SCD management. Gene therapy and CRISPR/Cas9-mediated gene editing hold the potential to correct the genetic defect at its source, offering hope for a cure. Hematopoietic stem cell transplantation (HSCT) also provides a curative option, with advancements making it accessible to a broader range of patients.

References

1. Ata F, Rahhal A, Malkawi L, Iqbal P, Khamees I, Alhiyari M, Yousaf Z, Qasim H, Alshurafa A, Sardar S, Javed S. Genotypic and phenotypic composition of sickle cell disease in the Arab population-a systematic review. Pharmacogenomics and Personalized Medicine. 2023:133-144.
2. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):224422-52.
3. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.
4. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-21.
5. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
6. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences. 2023;10((9): 72-75
7. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018; 5:157-158.
8. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-2487.
9. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41-.
10. Nur E, Biemond BJ, Otten HM, Brandjes DP, Schnog JJ, CURAMA Study Group. Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease management. American journal of hematology. 2011;86(6):484-849.
11. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research.2023;6(1):2768-2487.
12. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
13. Njar VE, Ogunnaya FU, Obeagu EI. Knowledge And Prevalence of The Sickle Cell Trait Among Undergraduate Students Of The University Of Calabar. Prevalence.;5(100):0-5.

14. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
15. Vona R, Sposi NM, Mattia L, Gambardella L, Straface E, Pietraforte D. Sickle cell disease: role of oxidative stress and antioxidant therapy. Antioxidants. 2021;10(2):296.
16. Wang Q, Zennadi R. The role of RBC oxidative stress in sickle cell disease: from the molecular basis to pathologic implications. Antioxidants. 2021;10(10):1608.
17. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-15.
18. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023;6(2):10-13.
19. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-48.
20. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022;2(1):218-234.
21. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic of Murtala Muhammad Specialist Hospital, Kano. blood.;11:16.
22. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-35.
23. Ifeanyi OE, Stella EI, Favour AA. Antioxidants in the Management of Sickle Cell Anaemia. Int J Hematol Blood Disord, 2018; 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018.
24. Buhari HA, Ahmad AS, Obeagu EI. Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. APPLIED SCIENCES (NIJBAS). 2023;4(1).
25. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015;8(3):261-265.
26. Obeagu EI. BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences. 2023;3(1):1-6.
27. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-507.
28. Hernansanz-Agustín P, Enríquez JA. Generation of reactive oxygen species by mitochondria. Antioxidants. 2021;10(3):415.
29. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023; 6 (2): 10-13.
30. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences. 2014;3(3):1000-1005.

31. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
32. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-163.
33. Ifeanyi E. Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. PARIPEX - INDIAN JOURNAL OF RESEARCH, 2015; 4(6): 258-259
34. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
35. Ifeanyi OE, Stanley MC, Nwakaego OB. Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michael okpara University of agriculture, Umudike, Abia state, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1046-1050.
36. Ifeanyi EO, Uzoma GO. Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. J Clin Med Res. 2020; 2:1-4.
37. Obeagu EI, Obeagu GU. Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:58-66.
38. Obeagu EI, Obeagu GU. Addressing Myths and Stigmas: Breaking Barriers in Adolescent Sickle Cell Disease Education. Elite Journal of Health Science. 2024;2(2):7-15.
39. Obeagu EI, Obeagu GU. Implications of climatic change on sickle cell anemia: A review. Medicine. 2024;103(6):e37127.
40. Orrico F, Laurance S, Lopez AC, Lefevre SD, Thomson L, Möller MN, Ostuni MA. Oxidative stress in healthy and pathological red blood cells. Biomolecules. 2023;13(8):1262.
41. Vona R, Sposi NM, Mattia L, Gambardella L, Straface E, Pietraforte D. Sickle cell disease: role of oxidative stress and antioxidant therapy. Antioxidants. 2021;10(2):296.
42. Obeagu EI. Chromium VI: A Silent Aggressor in Sickle Cell Anemia Pathophysiology. Elite Journal of Haematology, 2024; 2 (3).:81-95.
43. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. Annals of Medicine and Surgery. 2024:10-97.
44. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. Medicine. 2024 Jan 12;103(2):e36898.
45. Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes. Elite Journal of Health Science. 2024;2(2):1-9.
46. Obeagu EI, Obeagu GU. Dual Management: Diabetes and Sickle Cell Anemia in Patient Care. Elite Journal of Medicine. 2024;2(1):47-56.
47. Obeagu EI, Obeagu GU, Hauwa BA. Optimizing Maternal Health: Addressing Hemolysis in Pregnant Women with Sickle Cell Anemia. Journal home page: http://www. journalijiar. com.;12(01).

48. Obeagu EI, Obeagu GU. Synergistic Care Approaches: Integrating Diabetes and Sickle Cell Anemia Management. Elite Journal of Scientific Research and Review. 2024;2(1):51-64.
49. Obeagu EI, Obeagu GU. Improving Outcomes: Integrated Strategies for Diabetes and Sickle Cell Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):20-9.
50. Obeagu EI, Obeagu GU. The Role of Parents: Strengthening Adolescent Education for Sickle Cell Disease Prevention. Elite Journal of Public Health. 2024;2(1):15-21.
51. Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:67-80.
52. Obeagu EI, Obeagu GU. Overcoming Hurdles: Anemia Management in Malaria-Affected Childhood. Elite Journal of Laboratory Medicine. 2024;2(1):59-69.
53. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. Medicine (Baltimore). 2024 ;103(2):e36898. doi: 10.1097/MD.0000000000036898. PMID: 38215146; PMCID: PMC10783340.
54. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anaemia survival rates. Ann Med Surg (Lond). 2024;86(3):1570-1574. doi: 10.1097/MS9.0000000000001763. PMID: 38463100; PMCID: PMC10923353.
55. Obeagu EI, Obeagu GU. Malnutrition in sickle cell anemia: Prevalence, impact, and interventions: A Review. Medicine (Baltimore). 2024;103(20):e38164. doi: 10.1097/MD.0000000000038164. PMID: 38758879; PMCID: PMC11098235.
56. Obeagu EI, Obeagu GU. Management of diabetes mellitus patients with sickle cell anemia: Challenges and therapeutic approaches. Medicine (Baltimore). 2024;103(17):e37941. doi: 10.1097/MD.0000000000037941. PMID: 38669382; PMCID: PMC11049766.
57. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC. Nosocomial infections in sickle cell anemia patients: Prevention through multi-disciplinary approach: A review. Medicine (Baltimore). 2023;102(48):e36462. doi: 10.1097/MD.0000000000036462. PMID: 38050205; PMCID: PMC10695528.
58. Dilli PP, Obeagu E, Tamale A, Ajugwo A, Pius T, Makeri D. Update on the practice of premarital screening for sickle cell traits in Africa: a systematic review and meta-analysis. BMC Public Health. 2024 May 31;24(1):1467. doi: 10.1186/s12889-024-19001-y. PMID: 38822327; PMCID: PMC11143629.
59. Obeagu EI, Obeagu GU. Managing gastrointestinal challenges: Diarrhea in sickle cell anemia. Medicine (Baltimore). 2024;103(18):e38075. doi: 10.1097/MD.0000000000038075. PMID: 38701274; PMCID: PMC11062666.
60. Obeagu EI, Obeagu GU. Implications of climatic change on sickle cell anemia: A review. Medicine (Baltimore). 2024;103(6):e37127. doi: 10.1097/MD.0000000000037127. PMID: 38335412; PMCID: PMC10860944.
61. Obeagu EI. Eosinophilic dialogues: A molecular exploration of sickle cell anemia severity. Annals of Medicine and Surgery. 2024:10-97.
62. Pisoschi AM, Pop A, Iordache F, Stanca L, Predoi G, Serban AI. Oxidative stress mitigation by antioxidants-an overview on their chemistry and influences on health status. European Journal of Medicinal Chemistry. 2021; 209:112891.

63. Rushworth GF, Megson IL. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacology & therapeutics. 2014;141(2):150-159.
64. Park SH, Bao G. CRISPR/Cas9 gene editing for curing sickle cell disease. Transfusion and Apheresis Science. 2021;60(1):103060.
65. Strouse JJ, Heeney MM. Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. Pediatric blood & cancer. 2012;59(2):365-371.
66. Sadaf A, Quinn CT. L-glutamine for sickle cell disease: Knight or pawn? Experimental Biology and Medicine. 2020;245(2):146-54.
67. Chou ST, Fasano RM. Management of patients with sickle cell disease using transfusion therapy: guidelines and complications. Hematology/Oncology Clinics. 2016;30(3):591-608.
68. Leonard A, Tisdale J, Abraham A. Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy? British journal of haematology. 2020;189(3):408-423.
69. Silva DG, Junior EB, De Almeida EA, Bonini-Domingos CR. Oxidative stress in sickle cell disease: an overview of erythrocyte redox metabolism and current antioxidant therapeutic strategies. Free Radical Biology and Medicine. 2013; 65:1101-1109.
70. Ahmed SG, Ibrahim UA. A compendium of pathophysiologic basis of etiologic risk factors for painful vaso-occlusive crisis in sickle cell disease. Nigerian Journal of Basic and Clinical Sciences. 2017;14(2):57-77.
71. Lakkakula BV, Sahoo R, Verma H, Lakkakula S. Pain management issues as part of the comprehensive care of patients with sickle cell disease. Pain Management Nursing. 2018;19(6):558-572.
72. Brandow AM, Liem RI. Advances in the diagnosis and treatment of sickle cell disease. Journal of Hematology & Oncology. 2022;15(1):20.
73. Hoban MD, Orkin SH, Bauer DE. Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease. Blood, The Journal of the American Society of Hematology. 2016;127(7):839-848.